The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles

Kiran Musunuru; Roger S. Blumenthal

doi:10.1002/clc.20405

The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles

Kiran Musunuru, Roger S. Blumenthal

School of Medicine

Research output: Contribution to journal › Review article

Abstract

To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

Original language	English (US)
Pages (from-to)	288-290
Number of pages	3
Journal	Clinical Cardiology
Volume	31
Issue number	6
DOIs	https://doi.org/10.1002/clc.20405
State	Published - Jun 1 2008

Keywords

ENHANCE trial
Ezetimibe
Hypercholesterolemia

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/clc.20405

Fingerprint Dive into the research topics of 'The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles'. Together they form a unique fingerprint.

Cite this

Musunuru, K., & Blumenthal, R. S. (2008). The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles. Clinical Cardiology, 31(6), 288-290. https://doi.org/10.1002/clc.20405

@article{469fb540ba8d4caaba171b834ddf67a0,

title = "The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles",

abstract = "To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?",

keywords = "ENHANCE trial, Ezetimibe, Hypercholesterolemia",

author = "Kiran Musunuru and Blumenthal, {Roger S.}",

year = "2008",

month = jun,

day = "1",

doi = "10.1002/clc.20405",

language = "English (US)",

volume = "31",

pages = "288--290",

journal = "Clinical Cardiology",

issn = "0160-9289",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial

T2 - A return to first principles

AU - Musunuru, Kiran

AU - Blumenthal, Roger S.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

AB - To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

KW - ENHANCE trial

KW - Ezetimibe

KW - Hypercholesterolemia

UR - http://www.scopus.com/inward/record.url?scp=46949084239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46949084239&partnerID=8YFLogxK

U2 - 10.1002/clc.20405

DO - 10.1002/clc.20405

M3 - Review article

C2 - 18543313

AN - SCOPUS:46949084239

VL - 31

SP - 288

EP - 290

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 6

ER -